89 related articles for article (PubMed ID: 27103124)
1. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.
Jacobs BA; Meulenaar J; Rosing H; Pluim D; Tibben MM; de Vries N; Nuijen B; Huitema AD; Beijnen JH; Schellens JH; Marchetti S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1201-7. PubMed ID: 27103124
[TBL] [Abstract][Full Text] [Related]
2. Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling.
Meulenaar J; Keizer RJ; Beijnen JH; Schellens JH; Huitema AD; Nuijen B
J Pharm Sci; 2014 Feb; 103(2):478-84. PubMed ID: 24311366
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies.
Laille E; Savona MR; Scott BL; Boyd TE; Dong Q; Skikne B
J Clin Pharmacol; 2014 Jun; 54(6):630-9. PubMed ID: 24374798
[TBL] [Abstract][Full Text] [Related]
5. Formulation, development and in vitro characterization of modified release tablets of capecitabine.
Gaikwad SS; Avhad RD; Kalkotwar RS
Drug Dev Ind Pharm; 2020 Jan; 46(1):20-30. PubMed ID: 31778085
[No Abstract] [Full Text] [Related]
6. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
[TBL] [Abstract][Full Text] [Related]
7. Floating molecularly imprinted polymers based on liquid crystalline and polyhedral oligomeric silsesquioxanes for capecitabine sustained release.
Mo CE; Chai MH; Zhang LP; Ran RX; Huang YP; Liu ZS
Int J Pharm; 2019 Feb; 557():293-303. PubMed ID: 30599225
[TBL] [Abstract][Full Text] [Related]
8. Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial.
van Doorn L; Heersche N; de Man FM; de Bruijn P; Bijl I; Oomen-de Hoop E; Eskens FALM; van der Gaast A; Mathijssen RHJ; Bins S
Clin Pharmacol Ther; 2022 Feb; 111(2):455-460. PubMed ID: 34656072
[TBL] [Abstract][Full Text] [Related]
9. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers.
Yi S; Chung YJ; Kim TE; Shin HS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
Clin Ther; 2011 Jun; 33(6):728-37. PubMed ID: 21704237
[TBL] [Abstract][Full Text] [Related]
11. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
[TBL] [Abstract][Full Text] [Related]
12. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation.
Hing JP; Piotrovsky V; Kimko H; Brashear HR; Zhao Q
Curr Med Res Opin; 2005 Apr; 21(4):483-8. PubMed ID: 15899095
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.
Chachad S; Purandare S; Malhotra G; Naidu R
Cancer Chemother Pharmacol; 2013 Feb; 71(2):287-92. PubMed ID: 23090620
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease.
Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
Clin Neuropharmacol; 2012; 35(2):67-72. PubMed ID: 22377973
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
[TBL] [Abstract][Full Text] [Related]
17. Formulation of controlled-release pelubiprofen tablet using Kollidon(®) SR.
Song SH; Chae BR; Sohn SI; Yeom DW; Son HY; Kim JH; Kim SR; Lee SG; Choi YW
Int J Pharm; 2016 Sep; 511(2):864-75. PubMed ID: 27492018
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
[TBL] [Abstract][Full Text] [Related]
19. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.
Bialer M; Shekh-Ahmad T; Braun TL; Halvorsen MB
Epilepsia; 2013 Aug; 54(8):1444-52. PubMed ID: 23692553
[TBL] [Abstract][Full Text] [Related]
20. Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.
Molenaar-Kuijsten L; Jacobs BAW; Kurk SA; May AM; Dorlo TPC; Beijnen JH; Steeghs N; Huitema ADR
Cancer Med; 2021 Jul; 10(14):4781-4789. PubMed ID: 34121365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
